Daratumumab biosimilar - Xbrane
Alternative Names: Daratumumab biosimilar - Xbrane; Xdarzane™Latest Information Update: 16 Jul 2024
At a glance
- Originator Xbrane
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Preclinical Multiple myeloma